Key Drivers
- Cash Generation
- Debt Burden
- Low Coverage
AIAI Summary
SGRY has shifted from a “broken operator” to a portfolio-simplification story: strong same-facility growth and real free cash flow show the core business works, but the equity case still depends on asset sales and execution outpacing heavy leverage and sub-1x interest coverage. Near term, the key test is whether management can convert simplification into durable earnings power while holding the ~$15 support zone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Debt Burden
- •Low Coverage
SGRY remains cash-generative and reasonably profitable, but high leverage and weak interest coverage keep earnings negative despite a cheap-looking sales/book valuation.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Failed rebound
SGRY has trended lower over the last month, with $15.00 acting as key support and $15.95–$16.41 as resistance, so a break below support would weaken the setup while a move back above $16.00 would improve momentum.
Rebound to $15.95 on
Sentiment & News
Key News Insights:
- •Asset sale
- •Earnings beat
- •Guidance reaffirmed
Surgery Partners paired a strategic Idaho asset sale with Q2 results that beat expectations and reaffirmed guidance, prompting a positive stock reaction despite recent volatility.
The news is mildly positive for SGRY, as stronger operating results and steady outlook confirmation appear to outweigh short-term volatility and portfolio reshaping
Similar Companies in Healthcare
Other companies in the same sector with AI ratings